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Abstract
Background: Corticosterone reduction produced by adrenalectomy (ADX) induces apoptosis in
dentate gyrus (DG) of the hippocampus, an effect related to an increase in the expression of the
pro-apoptotic gene bax. However it has been reported that there is also an increase of the anti-
apoptotic gene bcl-2, suggesting the promotion of a neuroprotective phenomenon, perhaps related
to the expression of transforming growth factor β1 (TGF-β1). Thus, we have investigated whether
TGF-β1 levels are induced by ADX, and whether apoptosis is increased by blocking the expression
of TGF-β1 with an antisense oligonucleotide (ASO) administered intracerebrally in corticosterone
depleted rats.
Results: It was observed an increase of apoptosis in DG, 2 and 5 days after ADX, in agreement
with a reduction of corticosterone levels. However, the effect of ADX on the number of apoptotic
positive cells in DG was decreased 5 days after the lesion. In CA1–CA3 regions, the effect was only
observed 2 days after ADX. TGF-β1 mRNA levels were increased 2 days after ADX. The sustained
intracerebro-ventricular administration of a TGF-β1 ASO via an osmotic mini pump increased
apoptosis levels in CA and DG regions 5 days after ADX as well as sham-operated control animals.
No significant effect was observed following a scrambled-oligodeoxynucleotide treatment.
Conclusion: The changes in both the pattern and the magnitude of apoptotic-cell morphology
observed 2 and 5 days after ADX suggest that, as a consequence of the reduction of
corticosteroids, some trophic mechanisms restricting cell death to a particular time window are
elicited. Sustained intracerebral administration of TGF-β1 ASO increased the apoptosis promoted
by ADX, suggesting that TGF-β1 plays an anti-apoptotic role in vivo in hippocampus.
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Background
Recent studies have proposed that cytokines and growth
factors may influence the outcome of the damage induced
by neurodegenerative diseases [1,2]. Transforming growth
factor β1 (TGF-β1) represents the prototype of a large fam-
ily of growth factors that regulate cell growth, develop-
ment, differentiation and cell death [3,4].
TGF-βs have been detected at high concentrations in post-
mortem brain from patients with Parkinson's [5] and
Alzheimer's [6]diseases. Also, the presence of TGF-β1 pro-
motes an accumulation of cellular mature amyliod pro-
tein precursor in a microglial cell line [7]. The expression
of TGF-β1 is induced by hypoxia, ischemia and brain
trauma in several brain regions, including the hippocam-
pus [8-10]. However, whether the increased TGF-β1
expression observed in several neurological diseases has a
beneficial or detrimental effect on neurons remains
unclear.
Examples for both pro-apoptotic and neuroprotective
roles of TGFβ1 have been described. In vitro studies have
shown that immature cerebellar neurons exposed to TGF-
β1 die by apoptosis [11]. Also, addition of TGF-β1 to orga-
notypic cultures of postnatal mouse retina results in a
prominent apoptosis [12,13]. In contrast, pharmacologi-
cal administration of TGF-β1 prevents neuronal degener-
ation induced by excitotoxic injury in vitro [14] and
rescues hippocampal CA1 neurons from post-ischemic
cell death in vivo [15].
Targeted deletion of TGF-β1 in mice results in strain-
dependent defects and embryonic lethality [16,17].
Although TGFβ1 knock-out mice in the NIH genetic back-
ground live for a few weeks after birth, they present
increased numbers of apoptotic neurons in several brain
regions including the neocortex, caudate putamen and
cerebellum [18]. In addition, TGF-β1 deficiency in adult
Tgfβ1-/+ mice results in increased neuronal susceptibility
to excitotoxic injury in several structures including the
hippocampus [18]. These observations have led to pro-
pose that TGF-β1 is a neuroprotective cytokine.
Although the mechanisms underlying the neuroprotective
action of TGF-β1 have not been clarified, several reports
have suggested that this cytokine may have a direct effect
on apoptosis regulation. Administration of TGF-β1 to
neuronal cultures prevents β-amyloid-induced apoptosis,
probably by stimulating the expression of anti-apoptotic
proteins, such as BCL-2 and BCL-XL [19]. In primary hip-
pocampal neuronal cultures, it has been shown that TGF-
β1 protects against the excitotoxicity induced by NMDA-
dependent Ca2+ conductance, probably via induction of
BCL-2 gene expression [20]. In fact, some apoptotic sig-
nals promote mitochondrial membrane permeability, a
process controlled by BCL-2[21], leading to cytochrome C
release and pro-caspase-3 activation [22]. In agreement, it
has been shown that TGF-β1 can prevent neuronal apop-
tosis induced by caspase-3 [23].
Several reports have demonstrated that adrenalectomy
(ADX) induces apoptosis in the hippocampus [24-26],
probably by depletion of corticosterone levels. Indeed, it
has been found that ADX induces a strong decrease in
plasma corticosterone levels and brain changes, including
apoptosis and increased expression of TGF-β1 in hippoc-
ampus [27]. It has also been shown that ADX promotes
apoptosis in granular cells of the dentate gyrus (DG),
which can be prevented by corticosterone or aldosterone
replacement [25]. The adrenalectomy-induced loss of neg-
ative feedback at the hypothalamic level, also increases
the expression of corticotropin releasing hormone (CRH)
in several limbic brain regions which could induce neuro-
nal death [28]. However, intracerebroventricular infusion
of ADX rats with (9–41)-alpha-helical CRH, a CRH antag-
onist, does not decrease the number of degenerating gran-
ule cells in the hippocampus [28] suggesting that the
ADX-induced reduction in circulating levels of adrenal
steroids, but not the rise in hypothalamic CRH release, is
responsible for the apoptotic action on DG cells.
We have also reported that the ADX-induced apoptosis in
the DG is associated with an increase in the expression of
the pro-apoptotic gene bax [29] and activation of caspase-
9 [30]. However, ADX also stimulated the expression of
the anti-apoptotic gene bcl-2 [29]. Bye and collaborators
have shown that TGF-β1 levels are increased following
ADX, suggesting a neuroprotective effect for TGFβ1 [27].
Thus, we have investigated whether (i) TGF-β1 levels are
induced by ADX, (ii) TGF-β1 has a neuroprotective role
and (iii) intracerebral administration of an antisense oli-
gonucleotide directed against TGF-β1 in rats depleted of
corticosterone levels can block the TGF-β1-induced effects
Results
Adrenalectomy
To evaluate the effectiveness of ADX, serum corticosterone
concentrations were measured by RIA in all animals. Cor-
ticosterone serum levels were significantly decreased after
ADX (< 0.1 µg/dL; n = 20) compared to sham-operated
controls (22 ± 2.5 µg/dL; n = 10). To decrease the chances
of inducing any stress to the ADX- and sham-operated ani-
mals, special care was given to preserve the environmental
conditions where the experimental animals were kept
(temperature, light/dark cycle, humidity). The ADX ani-
mals also displayed a reduction in body weight gain
respect to sham-operated animals, in agreement with a
reduced corticosterone condition (data not shown).BMC Neuroscience 2006, 7:40 http://www.biomedcentral.com/1471-2202/7/40
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Apotosis induction in the hippocampus after 
adrenalectomy
As shown in Fig 1A, three morphological criteria were
considered for assessing an apoptotic features: (i)
pyknotic nucleus, (ii) nuclei with extensive and tight con-
densation of nuclear material into darkly stained balls,
and/or (iii) segmented nuclei [26]. One of these profiles
had to be fulfilled for counting as an apoptotic cell.
The density of cells showing apoptotic features was signif-
icantly increased in CA1–CA3 and in both supra- and
infra-pyramidal layers of the dentate gyrus when compar-
ing sections from 2-day ADX and sham-operated control
animals (Fig. 1B). Apoptosis was still prominent in both
blades of the DG 5 days after ADX (Fig. 1B). No significant
changes in the density of apoptotic cells were observed in
CA4 either 2 or 5 days after ADX.
Adrenalectomy induces changes in TGFβ1 mRNA level in 
the hippocampus
TGFβ1 expression as assessed by in situ hybridisation was
observed in different regions of the brain including neo-
cortex and hypothalamus. The hybridisation signal was
observed in the DG and cornus ammon fields CA1–CA3
of the hippocampus. Fig. 2 shows photomicrographs of
the hippocampal regions after in situ hybridisation for
TGF-β1 in brain sections from a sham-operated control
animal (A), or a 2-day (B) or 5-day (C) ADX animals. The
specificity of the hybridisation signal was evaluated with
an excess of unlabelled probe (D).
Sham-operated control animals showed TGF-β1 mRNA
positive hybridisation in the neuropil of the supra- and
infra-pyramidal layers of the DG (Fig. 2A). Expression of
TGF-β1 was also detected in CA1, but the intensity of the
hybridisation signal was weaker than in the DG. The CA3
and CA4 subfields showed the lowest intensity. Two days
after ADX, an increase in the intensity of the TGF-β1 signal
in the DG and CA1 was observed (Fig. 2B). However, 5
days after ADX the intensity of the hybridisation signal in
the hippocampus was similar to that observed in sections
from sham-operated animals (Fig. 2C). Also on the sub-
granular layer of DG there were some cells with positive
TGF-β1 mRNA signal, but the method used to measure
label intensity does not allow us to evaluate changes in
the number positive cells (not shown). No hybridisation
signal was observed when using an excess of unlabelled
probe (Fig. 2D). The results obtained by in situ hybridisa-
tion were quantified and the intensity of the hybridisation
signal was normalized to that of CA4, because the hybrid-
isation signal did not show any change in that area under
any of the experimental conditions tested (see Fig. 3).
Two days after ADX, the levels of TGF-β1 mRNA increased
in CA1 by approximately 30% with respect to sham-oper-
Adrenalectomy (ADX) induced apoptosis in hippocampus Figure 1
Adrenalectomy (ADX) induced apoptosis in hippoc-
ampus. Brain sections from 2-day (ADX-2) and 5-day 
(ADX-5) adrenalectomized animals were stained with 1% 
Cresyl Violet and the density of apoptotic cells in the left hip-
pocampus was estimated. Apoptotic cells were counted in 
ten non-successive 14 µm thick sections at 100× magnifica-
tion in Cornus Amonnis area (CA1, CA3, CA4) and supra- 
(SupDG) and infra- (InfDG) pyramidal layer of the dentate 
gyrus (DG). (A) Images illustrating the morphology of apop-
totic nuclei (small condensed nuclei, extensive and tight con-
densation of nuclear material into darkly stained balls or 
disassembled pyknotic cells). (B) Bar graph represents the 
mean ± SEM (4–5 animals per group) of the density of apop-
totic cells counted in each area for sham-operated animals 
(black columns), 2 days after ADX (dashed column) or 5 days 
after ADX (open column); the values obtained in 2-day and 
5-day sham-operated animals were pooled because no differ-
ences were observed with time after the sham operation. 
The data was analysed using the non parametric Kruskal-
Wallis test, followed by Dunns post-hoc test. * p < 0.05 and 
** p < 0.01 compared to the corresponding sham-operated 
control. Scale bar = 20 µm.
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ated animals (Fig. 3). Also, a significant increase in TGF-
β1 mRNA was observed in supra- and infra-pyramidal lay-
ers of the DG (by 70% and 50%, respectively). In contrast,
TGF-β1 mRNA levels in CA3 were not modified by ADX.
TGF-β1 mRNA returned to sham-operated baseline levels
5 days after ADX in CA1 and the two blades of the DG.
Lateral ventricle administration (i.c.v.) of an 
oligodeoxynucleotide antisense for TGF-β1 exacerbates 
hippocampal apoptosis induced by adrenalectomy
To evaluate the role of TGF-β1 in the hippocampus under
control and ADX conditions, an antisense oligonucleotide
to TGF-β1 that has been successfully used by others [31]
was infused into the lateral ventricle starting 2 days before
ADX. TGF-β1 antisense produced an enhancement in the
density of nuclei with apoptotic features in the DG 5 days
after ADX (Fig. 4C) when compared to either sham-oper-
ated i.c.v. saline-infused (Fig. 4A) or to ADX i.c.v. saline-
infused animals (Fig. 4B).
Semiquantitative analysis demonstrated a >2-fold
increase in the density of apoptotic cells in both blades of
the DG, compared to that observed in sham- or ADX-
operated animals infused with saline (Fig. 5A). This effect
was specific because the administration of scrambled oli-
gonucleotide (SCRO) did not have any effect compared to
that seen in ADX animals treated with saline (Fig. 5A).
Analysis of the results revealed that the density of apop-
totic cells in the CA1 or CA4 regions was not statistically
different between ASO- and SCRO- infused ADX rats (Fig.
5B). Nevertheless, administration of SCRO but not ASO
to ADX animals induced a statistically significant increase
in the density of apoptotic cells in the CA3 area compared
to those in saline-infused rats (Fig. 5B). We also tried to
correlate changes in TGF-β1 mRNA levels with TGF-β1
immunoreactivity in the hippocampus. However, the
antibodies available did not produce positive immunore-
action neither in hippocampal slices nor control tissue
(adrenal gland).
Lateral ventricle administration (i.c.v.) of an antisense 
oligodeoxynucleotide against TGF-β1 promotes 
hippocampal apoptosis in control animals
The effect of antisense oligonucleotide against TGF-β1 in
sham-operated control animals in the CA3 region are
illustrated in Fig. 6A. Compared to saline-infused con-
trols, sections from sham-operated animals treated with
ASO showed an increase in the number of apoptotic
ADX increased TGF-β1 NA expression in the hippocampus Figure 2
ADX increased TGF-β1 NA expression in the hippocampus. Photomicrographs show the changes in TGF-β1 mRNA 
levels in hippocampus of: (A) control (sham-operated), (B) 2 days after ADX (ADX-2), and (C) 5 days after ADX (ADX-5) ani-
mals. The in situ hybridisation was performed using a digoxigenin-labelled oligonucleotide probe complementary to TGF-β1 
mRNA (524 pb – 563 bp; accession number NM_021578.1). The specificity of the hybridisation was evaluated using a 100-fold 
excess of unlabelled oligonucleotide (D). Scale bar = 500 µm.BMC Neuroscience 2006, 7:40 http://www.biomedcentral.com/1471-2202/7/40
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nuclei in the CA3 region whether the sections were
observed at low (Fig. 6A, 40×) or high (Fig. 6A, 100×)
magnification.
Semiquantitative analysis revealed a significant increase
in the density of hippocampal cells undergoing apoptosis
following ASO administration (Fig. 6B; p < 0.01 for the
CA3 region and p < 0.05 for both blades of the DG when
comparing with control untreated animals). No statisti-
cally significant effects were observed between control
and SCRO-infused animals in any of the hippocampal
areas studied.
Discussion
The present study showed that ADX induced a strong
decrease in plasma corticosterone levels, and increased
TGFβ-1 expression and apoptosis in the hippocampus.
Intracerebroventricular administration of antisense oligonu- cleotide directed against TGF-β1 increased the density of  apoptotic cells in the dentate gyrus after five days of ADX Figure 4
Intracerebroventricular administration of antisense 
oligonucleotide directed against TGF-β1 increased 
the density of apoptotic cells in the dentate gyrus 
after five days of ADX. The ASO, SCRO (10 µg/day) or 
vehicle were stereotaxically delivered into the lateral left 
ventricle, via a cannula connected to a subcutaneously 
implanted Alzet osmotic mini-pump, delivering the corre-
sponding solution during 7 days. The animals were adrenalec-
tomized, or sham-operated 2 days after the beginning of the 
i.c.v. treatment and euthanized 5 days after. Photomicro-
graphs illustrate changes in apoptotic morphology in the 
suprapyramidal layer of the DG of: (A) control (saline-
treated, sham-operated), (B) saline-treated, adrenalect-
omized (ADX-5), and (C) ASO TGF-β1-treated, adrenalect-
omized (ADX-5/TGF-β1 ASO) animals. Arrowheads denote 
pyknotic nuclei, nuclei containing clumped chromatin disas-
sembling and degenerating nuclei. Scale bar = 20 µm.
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The decrease of corticosterone plasma levels by ADX
should be accompanied by a decrease of aldosterone lev-
els [25], and by an increase of hypothalamic secretion of
CRH also accompanied by a raise in CRH expression in
several limbic brain regions which could induce neuronal
death [28]. The effect of ADX on apoptosis is probably
due to corticosterone and aldosterone depletion, because
the ADX-induction of apoptosis in granular cells of the
DG is prevented by corticosterone or aldosterone replace-
ment, but not by (9–41)-alpha-helical CRH, a CRH antag-
onist [28], indicating that the adrenal steroids exert a
trophic influence on DG cells.
In agreement with a reduction in serum levels of corticos-
terone, apoptosis increased in the DG, 2 and 5 days after
ADX. Also, a reduction (40%) in the density of apoptotic
cells was observed in the infrapyramidal layer of DG 5
days after ADX, while corticosterone levels remained
reduced. Several changes have been reported to occur in
the DG after ADX. TUNEL positive cells in the hippocam-
pus are more prevalent in the DG 5 days after ADX [26].
Moreover, induction of bax  [29] and activation of cas-
pases- 3 [32] and -9 [30] have been reported in the DG
after short-term ADX. In contrast, the increase in density
of apoptotic cells in the CA1–CA3 regions was only
observed 2 days after ADX. The difference in both the tem-
Quantitative analysis of the effect of TGF-β1 ASO and SRO administration into the left lateral ventricle on hippocampal apop- totic morphology 5 days after adrenalectomy (ADX) Figure 5
Quantitative analysis of the effect of TGF-β1 ASO and SRO administration into the left lateral ventricle on hip-
pocampal apoptotic morphology 5 days after adrenalectomy (ADX). Data represent the density of apoptotic cells 
(mean ± SEM) in the hippocampus ipsilateral to the side infused with the oligodeoxynucleotide or a saline solution. (A) Apop-
tosis observed in the suprapyramidal and infrapyramidal of dentate gyrus. Black columns, saline infused sham-operated animals; 
white columns, saline infused, ADX-5 animals; gray columns TGF-β1 ASO infused ADX-5 animals; dashed columns, TGF-β1 
SCR infused ADX-5 animals. * p < 0.05 vs control; *** p < 0.01 vs control; # p < 0.05 vs ADX-5; ## p < 0.01 vs ADX-5, ≠ p < 
0.05 vs ADX/TGF-β1 ASO. (B) Inset representing Cornus Amonis areas. Black columns, saline infused, sham-operated animals; 
white columns, saline infused, ADX-5 animals; gray columns TGF-β1 ASO infused ADX-5 animals; dashed columns, TGF-β1 
SCRO infused ADX-5 animals. * p < 0.05 vs control; # p < 0.05 vs ADX-5.
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TGF-β1 antisense oligonucleotide (ASO) administration into the left lateral ventricle induced hippocampal apoptotic morphol- ogy in a sham-operated control rat Figure 6
TGF-β1 antisense oligonucleotide (ASO) administration into the left lateral ventricle induced hippocampal apop-
totic morphology in a sham-operated control rat. (A) Photomicrographs show the changes of apoptotic morphology in CA3 
hippocampal subfield induced byTGF-β1 ASO i.c.v. treatment in sham-operated control animal. Upper microphotograph shows a 40× 
magnification (scale bar = 50 µm). The middle microphotographs show details of the same field at 100× magnification (scale bar = 20 
µm). The lower microphotograph show CA3 area from a saline infused sham-operated animal. (B) Data represent the density of 
apoptotic cells (mean ± SEM from 4–5 animals) in the hippocampal areas ipsilateral to the side infused with saline (black bar), ASO 
(gray bar) or SCRO (open bar). * p < 0.05 vs control; ** p < 0.01 vs control; # p < 0.05 vs TGF-β1 ASO.
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poral pattern and the magnitude of apoptotic-cell mor-
phology observed 2 and 5 days after ADX in these
hippocampal regions suggest that under these experimen-
tal conditions there are some trophic mechanisms restrict-
ing cell death to a particular time window after the insult
provoked by the reduction of corticosteroids resulting
from ADX. This restriction in cell death is probably related
to the induction of the anti-apoptotic gene bcl-2 [29]. In
agreement with this hypothesis, it has been reported that
the removal of corticosteroids (3 days after ADX) triggers
a specific gene expression profile in surviving dentate
granule cells including the antiapoptotic bcl-2 gene, pro-
viding them the chance of survival and probably making
them more resistant to the apoptosis observed after ADX
[33].
Several types of brain injuries are able to induce the syn-
thesis and/or the release of different growth factors (e.g.,
neurotrophins and cytokines) [1,2] providing neuropro-
tection [14,15]. TGF-β1, which is induced in the hippoc-
ampus after ADX [27] (and in this study), may also
participate in the neuroprotective mechanisms. TGF-β1 is
markedly increased in rat cerebral cortex and hippocam-
pus after trauma, electrolytic lesion of the entorhinal cor-
tex, or ischemia [8-10,34]. Moreover, the administration
of TGF-β1 to neuronal cultures prevents the apoptosis
induced by the β-amyloid through the induction of the
antiapoptotic BCL-2 and BCL-XL proteins [19].
The majority of the studies performed to investigate the
neuroprotective role of TGF-β1 are based on models
where neuronal death is a continuum between necrosis
and apoptosis [14,15], making it difficult to establish
which one of these processes prevails. These processes are
associated with different mechanisms buffering cell death.
To differentiate which one of these processes is relevant,
we used a model in which apoptosis takes place in a rather
selective manner [24-26,29]. ADX has been proposed as a
good in vivo model for hippocampal apoptosis, because it
is a non invasive procedure to the brain and, as it is also
shown in this study, it triggers apoptosis by corticosteroid
and aldosterone reduction only [24-26]. Thus, we have
evaluated with the ADX model if the expression of TGF-β1
is modified.
Primary rat hippocampal neuronal culture secretes TGF-
β1 making feasible an autocrine and/or paracrine role in
the hippocampus [35]. TGF-β1 mRNA and its protein
have been localised in both hippocampal neurons and
glia [32,36]. Hippocampal CA1–CA4 neurons display
immunoreactivity for active TGF-β1 under physiological
conditions, although mRNA expression was low [36,37].
These evidences suggest basal expression of TGF-β1 in the
hippocampus. In the present study, expression of TGF-β1
mRNA was observed in the neuropil of the supra and
infra-pyramidal layers of DG and comparatively weaker in
the CA1 and CA3 subfields. Taken together, these results
indicate the existence of basal expression of TGF-β1 in the
hippocampus.
Labelling for TGF-β1 mRNA over OX-42-positive micro-
glia with an activated morphology in the dentate gyrus
granule cell layer has been observed 3 days after ADX [32].
In our studies, the expression of TGF-β1 mRNA showed a
transient increase in both CA1 and supra- and infrapyram-
idal-layers of the DG 2 days after ADX with values return-
ing to control levels 5 days after ADX. The plastic changes
observed in the present study could be related to the per-
manent reduction of corticosteroid plasma levels and/or
to cell death promoted by ADX.
It is well established that corticosteroids regulate many
physiological processes through their binding to gluco-
corticoid receptors (GR). The ligand-activated receptor
dimer activates gene expression by binding to specific
DNA sequences (glucocorticoid response element, GRE)
in the promoter regions of glucocorticoid-regulated genes
[38]. In contrast to the regulation of these classical GREs,
the repression of negatively regulated target genes is medi-
ated by trans-repression and/or by the binding of the GR
to negative GREs (nGREs) [38]. It is possible that nGREs
are also present in the TGF-β1 gene promoter region. The
corticosterone reduction switches off the action of the
nGREs, enhancing the expression of TGF-β1. At least in
humans, it is known that human TGF-β1 gene has a GRE
in its promoter [39], probably acting as a repressor of the
TGF-β1 gene expression. Indeed, the increase in the
expression of hippocampal TGF-β1 by ADX is prevented
by corticosterone administration [40]. However, this
mechanism cannot totally account for the normalization
of TGF-β1 mRNA levels observed 5 days after ADX in our
experiments.
During the early stages of apoptosis, phosphatidylserine is
exposed to the cell surface, triggering cell engulfment by
neighboring cells or phagocytes. However, exposure of
phosphatidyl-serine to the outer face of plasma mem-
brane in the apoptotic cells acts as a stimulus to induce the
expression of TGF-β1 by microglia [41]. Therefore, the up-
regulation of TGF-β1 observed following ADX may result
from neuronal death itself, similar to that reported by
other scientists [8-10,42]. However, other authors have
observed an increase in TGF-β1 expression 7 days after
ADX although in different rat strains [40]. Recently, the
same authors showed the time course of TGF-β1 mRNA
expression in the DG which is increased 2 days after ADX
(similar to our results) reaching maximum 3 days after
ADX [32]. Also the levels of expression are mantained 7
days after ADX, a period where the apoptosis is still occur-
ring. However these authors did not study the TGF-β1BMC Neuroscience 2006, 7:40 http://www.biomedcentral.com/1471-2202/7/40
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expression after 5 or more days after ADX. More recently,
Battista et al [43] showed an increase in TGF-β1 by RT-
PCR in the hippocampus 3 days after ADX. It is possible
that the ADX-induced expression of TGF-β1 could be
biphasic, i.e. an early generalized induction of TGF-β1
mRNA in the hippocampus (CA and DG areas) which is
maintained for a few days after ADX (1–3 days) and there-
after the gene is re-expressed between 5–7 days of ADX
and persists over ADX period in areas undergoing neuro-
nal death, i.e. in the DG. A similar pattern of TGF-β1
induction has been reported in the post-ischemic adult rat
hippocampus [8,36].
Thus, it was interesting to study the effect of blocking TGF-
β1 mRNA translation by an antisense oligonucleotide. We
used this approach instead of blocking the TGF-β1 pep-
tide using neutralizing antibodies, because the oligonu-
cleotide is more diffusible that an antibody. Also the
administration of a neutralizing antibody requires a single
application near to the site of interest, i.e. close to the DG
or CA areas, making it feasible to induce tissue damage
and by this means microglia activation. We used a TGF-β1
ASO developed by Le Roy et al. [31], who demonstrated
that antisense prevented the translation of TGF-β1 mRNA
by Leydig cells and, consequently, reduced TGF-β1 immu-
noreactivity, which was not observed following adminis-
tration of a corresponding SCRO
In this study, sustained i.c.v. administration of that TGF-
β1 ASO via an osmotic mini pump increased apoptosis
levels in CA and DG regions 5 days after ADX, but also in
sham-operated control animals. Indeed, when TGF-β1
ASO was administered to sham-operated animals, apop-
totic cells were increased in both CA3 and DG regions,
while in ADX-animals the effect was restricted to the DG.
The CA3 area shows low levels of TGF-β1 mRNA, both in
control and ADX animals, indicating that its expression is
independent of corticosterone levels. The finding that
ASO administration promotes apoptosis in CA3 led us to
propose that low levels of TGF-β1 are enough to protect
cells against apoptosis in this hippocampal subfield. Also
TGF-β1 is capable of suppressing the levels of TNF-α [44],
suggesting that the reduction of TGF-β1 by ASO treatment
might induce the expression of this pro-inflammatory
cytokine, that can also promote apoptosis through its
receptor[45]. It is remarkable that CA3 field is normally
resistant to ischemia [46] and ADX (5 days, Fig. 1) and
this phenomena could be achieved through a tonic
expression of TGF-β1 [36]. Interestingly TGF-β1 defi-
ciency in adult Tgfβ1-/+ mice results in increased neuro-
nal susceptibility to excitotoxic injury in several structures
including the hippocampus [18].
The lack of effect of the TGF-β1 ASO on ADX CA3 may be
explained by other neurotrophic factors elicited by the
lesion. In fact, it has been shown that ADX promotes the
induction of BDNF in pyramidal regions of the hippoc-
ampus [47,48].
In the present study, SCRO administration did not induce
any effect on apoptosis levels, except in CA3 of ADX ani-
mals, where there was an increase of apoptosis levels fol-
lowing intracerebral SCRO administration. While we do
not have any explanation for this effect, it may be specu-
lated that is probably due to the presence of an unmethyl-
ated CpG dinucleotide in the SCRO sequence. This a
motif that has been reported to stimulate microglia and
astrocytes in the CNS, releasing TNF-α, a pro-inflamatory
cytokine[49]. This cytokine may exert in turn neuronal
injury in vulnerable regions [50], under conditions where
there is a decrease of corticosterone levels, like following
ADX.
Conclusion
ADX promotes a permanent decrease of plasma corticoid
levels and transient increase of apoptosis and TGF-β1
expression in hippocampus, reaching a maximum 2 days
after ADX. The effect was mainly observed in supra- and
infra-layers of the DG, where the expression of TGF-β1
mRNA was stronger than in any other regions of the hip-
pocampus.
Administration of a TGF-β1 ASO promoted hippocampal
apoptosis, both in sham- and ADX-animals. In sham-
operated animals, apoptosis was increased in both CA3
and DG regions, while in ADX-animals the effect was
restricted to the DG. The lack of effect of the TGF-β1 ASO
on ADX CA3 can be explained by other neurotrophic fac-
tors elicited by the lesion.
These observations, together with previously published
reports indicating an increase in the expression of TGF-β1
in response to brain injuries, suggest that TGF-β1 exerts
neuroprotection in adult nervous system.
Methods
Animals
Adult (200–220 g) male Sprague-Dawley rats were used in
all experiments. The animals were kept under temperature
(22°C–24°C), humidity (50%) and 12 h regulated light-
dark cycle conditions, with food and water ad libitum. All
procedures and care of the animals were conducted fol-
lowing protocols approved by the local Institutional Ethi-
cal Committee of the Faculty of Chemical and
Pharmaceutical Sciences, University of Chile, in compli-
ance with guidelines published in the National Institutes
of Health Guide for the care and use of laboratory animals.BMC Neuroscience 2006, 7:40 http://www.biomedcentral.com/1471-2202/7/40
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Design and synthesis of oligodeoxynucleotides
All phosphorothioates oligodeoxynucleotides were pur-
chased in purified form from Integrated DNA technolo-
gies (INC, Coralville, IA, USA), single-end capped
(sulphur modification on the phosphate group between
the first and last base pairs), displaying low toxicity for the
central nervous system [51,52]. Oligodeoxynucleotides
were reconstituted in ultra-filtered saline at a concentra-
tion of 417 pg/µL. The antisense to TGF-β1 was a 15 base
oligomer that had been previously used in its full phos-
phorothioate form [31]. Its sequence was 5'-G-S-GAG-
GGCGGCATGG-S-G-3' (the -S- denotes locations of the
sulphur modification) and complementary to the transla-
tion-initiation region of the rat TGF-β1 mRNA (410–424
pb of rat TGF-β1 cDNA; Genbank accession number
NM_0215781). A scrambled oligodeoxynucleotide
(SCRO), which had a randomly ordered but identical base
content to the antisense was used as a control. Its
sequence was 5'-A-S-GGTGGGAGGCGGC-S-G-3'. All oli-
godeoxynucleotides used in this study were subjected to a
BLASTN search on the National Center for Biotechnology
Information BLAST server using the Genbank database.
The antisense oligodeoxynucleotide sequence had a 100%
positive match for its mRNA sequence. The SCRO pro-
duced no positive matches.
Surgery
Adrenalectomy (ADX)
Animals were anaesthetised with isofluorane (1.5% v/v
air) and subjected to a bilateral ADX. The animals were
kept with a 0.9% NaCl drinking solution to compensate
the sodium deficit induced by the ADX. The sham-oper-
ated rats underwent a skin and lumbar muscle incision,
leaving the adrenal glands untouched.
Oligodeoxynucleotide-i.c.v. administration
The rats were anaesthetised as above and fixed in a David
Kopt stereotaxic frame. Guide cannulae were implanted
into the left lateral ventricle (i.c.v., intra cerebro-ventricu-
lar infusion) (Bregma -0.8 mm, lateral 1.5 with a depth of
3.7 mm below the dura) according to Paxinos and Watson
[53]. The cannula was then connected by a catheter to an
ALZET® mini-osmotic pump (Model 2001; Palo Alto, CA)
implanted subcutaneously in the scapular region deliver-
ing at a rate of 10 µg oligodeoxynucleotide/day. For
saline-treated control animals, the ALZET pump was filled
with sterile saline solution. After 2 days of oligodeoxynu-
cleotide infusion, the rats were subjected to either ADX or
a sham operation as described above and maintained for
further 5 days after surgery.
Tissue fixation
Two or five days after ADX, the animals were anesthetized
by intramuscular injection of xylazine (5 mg/kg) and ket-
amine (50 mg/kg). A blood sample was taken from the
heart and the obtained serum was kept at -20°C for corti-
costerone determination. Animals were then transcar-
dially perfused with 100 mL of 0.9% NaCl followed by
500 mL of 4% paraformaldehyde in 0.1 M phosphate
buffer (PB) pH 7.4. The brain was dissected from the skull,
post-fixed in the same buffer overnight and then
immersed in 30% sucrose in 0.1 M phosphate buffered
saline (PBS) at 4°C for 2 days. Coronal sections (14 µm
thick) were sliced from the frozen fixed brains and proc-
essed for Nissl staining.
Apoptotic morphology
Sections were dipped in 1% Cresyl Violet for 20 min,
dehydrated in alcohol and mounted in Entellan (Merck,
Darmstadt, Germany). Apoptotic nuclei were identified
by using the criteria proposed by Greiner et al [26]. In
short, one of the following criteria had to be fulfilled to
count for an apoptotic cell: (i) pyknotic nucleus; (ii)
extensive and tight condensation of nuclear material into
darkly stained balls, and/or (iii) segmented nuclei [26].
The density of apoptotic cells per hemisection was calcu-
lated from ten non-successive coronal sections inspected
at 100× for each animal [29], and expressed as the means
± SEM of 4–5 animals.
In situ hybridisation for TGFβ1 mRNA
The in situ hybridisation was conducted with an oligode-
oxynucleotide probe complementary to TGF-β1 mRNA
(524–563 pb access number NM_021578.1) labelled with
a digoxigenin oligonucleotide 3'-OH tailing kit (Roche,
Molecular Biochemicals, Mannheim, Germany). The
hybridisation was conducted as previously described [29].
The specificity of the hybridisation was evaluated by the
use of 100 fold excess of the unlabelled oligodeoxynucle-
otide. For semiquantitative analysis, densitometric meas-
urements of each hippocampal subfield were analysed
using UN-SCAN-IT software (Silk Scientific Inc. Orem,
UT, USA). A grey scale was used for measuring the inten-
sity of the signals (pixels) observed in the hippocampal
regions, i.e. the darkest staining the highest optical den-
sity; the lightest staining the lowest optical density. The
hybridisation signal in the stratum radiatum was consid-
ered as background and was subtracted from the optical
density values obtained in the hippocampal cell layers.
For each animal the value represents the average from 4–
5 brain sections. In order to normalize the different exper-
imental conditions, all the data are expressed as optical
density respect to the CA4, because the intensity in that
region did not change following any of the experimental
conditions.
Corticosterone radio immunoassay
Corticosterone levels were determined by RIA according
to the instruction of the manufacturer (Sigma, St. Louis,
MO, USA), as described previously [26]. In short, the ratBMC Neuroscience 2006, 7:40 http://www.biomedcentral.com/1471-2202/7/40
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serum was diluted 1:10 in 0.05 M Tris-HCl, pH 8.0, con-
taining 0.1 M NaCl, 0.1% BSA and then warmed at 50°C
for 30 min. The anti-corticosterone antibody (Sigma-
Aldrich, St Louis MO, USA; rabbit) was added to 0.1 ml
sample or to 0.1 ml of the corticosterone standard (31–
1000 pg). After 30 min of incubation, a 3H-corticosterone
tracer (specific activity 100 Ci/mmol, Sigma-Aldrich, St
Louis MO, USA) was added to each tube and incubated
for 1 hour at 37°C. Finally, 0.2 ml cold dextran coated
charcoal was added to the standard and/or samples, cen-
trifuged at 2000 × g for 15 minutes at 4°C. The radioactiv-
ity was measured in the supernatant. The quantity of
corticosterone in serum samples was estimated using the
Prism software 4.0 (GraphPad Software, San Diego, CA).
Intra and inter assays variation was less than 5%. The min-
imal detectable level of corticosterone was 0.1 µg/assay.
Statistical analysis
Descriptive statistic for individual parameters are reported
as mean ± SEM. The Prism software 4.0 (GraphPad Soft-
ware, San Diego, CA) was used for statistical analysis and
graph representation. Treatment effect was assayed with
the non parametric Kruskal-Wallis test, followed by
Dunns post-hoc test. Differences were considered to be
significant when the probability of their occurrence as a
result of chance alone was less than 5%.
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